Ahead of Elanders' Q4 report, we lower 2025E adjusted EBITA by 2% and 2026E-27E by 6%, due to FX and...
Redeye comments on Freja’s Q4 ARR and SaaS metrics.
Redeye is positive about Optomed’s partnership with Aireen and the EU approval for AI integration wi...
Redeye is optimistic about the directed share issue announced last week and a potential subsequent o...
Redeye provides a preview ahead of Tradedoubler’s Q4 2025 report, scheduled for publication on 12 Fe...
* Q4e: soft growth, but margins supported by restructuring programme * Estimate cuts on FX and produ...
At SEB’s Nordic Seminar, Bactiguard’s CEO, Christine Lind, presented its technology and provided an ...
At SEB’s Nordic Seminar, CEO Mark Waugh presented OssDsign to investors just seven days after being ...
Redeye is positive about Corline’s directed share issue and loan agreement with Kardium.
Redeye retains its positive view on q.beyond, maintaining our Base Case at EUR 1.
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q4 2025 ended a...
At SEB’s Nordic Seminar, CFO Per Brilioth discussed the milestones VNV achieved during 2025, includi...
Redeye comments on the news that the TRANBERG Thermal Therapy System for focal laser ablation (FLA) ...
The UK and Germany signal uncertainty after management communicated in mid-December that it will not...
At SEB’s Nordic Seminar, Gofore's CEO emphasised that that the company is currently much better equi...
* Acquisition of Volvo Construction Equipment dealer in Iowa * Adds 8% to PF'26e EBIT, 13x acquisiti...
Redeye’s conviction in BI-1808 increases with the latest readout in platinum-resistant ovarian cance...
Aneo has completed its recommended public cash offer and now controls approximately 92.
Redeye provides a brief comment on the unexpected announcement that Episurf Medical intends to acqui...
Redeye initiates coverage on Hacksaw, a fast-growing and highly profitable Remote Gaming Server (RGS...
